Market Place: Genzyme to Make Offer for AnorMed
20790
In a rare hostile bid, Genzyme said it would make an offer for AnorMed, a Canadian company that had spurned previous acquisition approaches.
204544
Will Genzyme's Campath get approval?
757229
Genzyme Corp. of Cambridge and German partner Bayer Schering Pharma AG said they have begun phase 3 trials of their cancer drug Campath to treat multiple sclerosis. The companies said they plan on reporting phase 2 results Oct. 14. After phase 3, they hope to seek US regulatory approval in 2011 to market the drug, also known as alemtuzumab, to ...
598449
NEW YORK  - An enzyme has been recently identified that is able to degrade gluten in a laboratory simulation of the gastrointestinal tract.
138104
Human Genome Sciences could see more than $180 million from a new deal with drug maker GlaxoSmithKline. Glaxo has acquired exclusive rights to an experimental drug called Albugon, which Human Genome Sciences
291560
Gilead Sciences, which makes drugs to treat H.I.V., announced plans to buy a rival, Myogen, for about $2.5 billion in cash.
572919
Biotech titan Genzyme (Nasdaq: GENZ) has its roots in the treatment of rare genetic diseases and also has a significant presence in the treatment of renal diseases and providing diagnostic testing services.
536259
Genzyme Corp.'s not-yet-completed $1 billion acquisition of Ilex Oncology Inc. appeared to pay off yesterday when an advisory committee to the Food and Drug Administration recommended the agency approve Ilex's experimental cancer treatment for children with certain types of leukemia.
713941
GlaxoSmithKline Plc  has bought global rights to Danish biotech company Genmab's  most promising new drug, a treatment for leukemia, in a record deal worth up to $2.1 billion, the two firms said on Tuesday.
336171
YESTERDAY Close $75.73 Change +$2.22 52-WEEK High $76.90 Low $58.71 Genzyme Corp. of Cambridge said profit jumped tenfold as sales increased for its medicines for rare genetic disorders, some of the world's costliest drugs. The company gained 3 percent in New York trading.
723686
FOSTER CITY, Calif. -- Gilead Sciences Inc., a drug research company, said Monday it plans to buy Myogen Inc. for about $2.5 billion in cash, giving Gilead access to Myogen's heart-drug candidates.
412704
NEW YORK (CBS.MW) -- The Food and Drug Administration has approved Genzyme Corp. and Bioenvision Inc.&#39;s treatment for the most common type of childhood leukemia, sending shares of both companies higher Wednesday.
490579
Biotechnology company Genzyme Corp. said one of its experimental treatments for pain associated with osteoarthritis of the knee works no better than traditional steroids. The therapy, hylastan, is one of several viscosupplements -- injectable substances that lubricate the joints -- that Genzyme is developing to succeed its existing product, Synvisc.
50296
Merck & Company said it had signed a deal for an authorized generic form of its blockbuster osteoporosis drug Fosamax to become available in February.
137099
The pharmaceutical files another marketing application.
17876
Gene therapies could one day offer relief from allergies such as hayfever, claim UK and Swiss scientists.
763508
NEW YORK DEC 29, 2004  - Genzyme Corp. announced Wednesday that the US Food and Drug Administration (FDA) has approved the nucleoside analogue clofarabine (Clolar) for the treatment of children